Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Scott P. Levick PhD

Scott P. Levick PhD

Assistant Professor

Institution: Medical College of Wisconsin
Department: Pharmacology and Toxicology
Program: Program Development

Member of the Cardiovascular Center


  • Novel Omega-3 Fatty Acid Epoxygenase Metabolite Reduces Kidney Fibrosis. (Sharma A, Hye Khan MA, Levick SP, Lee KS, Hammock BD, Imig JD) Int J Mol Sci 2016 May 18;17(5) PMID: 27213332 PMCID: PMC4881572 05/24/2016
  • Targeting substance P and relaxin: A future combination therapy approach for heart failure? (Levick SP, Meléndez GC) Int J Cardiol 2016 Feb 1;204:154-5 PMID: 26657613 12/15/2015
  • Substance P induces cardioprotection in ischemia-reperfusion via activation of AKT. (Jubair S, Li J, Dehlin HM, Manteufel EJ, Goldspink PH, Levick SP, Janicki JS) Am J Physiol Heart Circ Physiol 2015 Aug 15;309(4):H676-84 PMID: 26071541 PMCID: PMC4537946 06/14/2015
  • Differential Effects of Prevention and Reversal Treatment with Lisinopril on Left Ventricular Remodelling in a Rat Model of Heart Failure. (Brower GL, Levick SP, Janicki JS) Heart Lung Circ 2015 Sep;24(9):919-24 PMID: 25837018 PMCID: PMC4564313 04/04/2015
  • Non-human primate and rat cardiac fibroblasts show similar extracellular matrix-related and cellular adhesion gene responses to substance P. (Meléndez GC, Manteufel EJ, Dehlin HM, Register TC, Levick SP) Heart Lung Circ 2015 Apr;24(4):395-403 PMID: 25550118 PMCID: PMC4492475 01/01/2015
  • The emerging prominence of the cardiac mast cell as a potent mediator of adverse myocardial remodeling. (Janicki JS, Brower GL, Levick SP) Methods Mol Biol 2015;1220:121-39 PMID: 25388248 PMCID: PMC4422981 11/13/2014
  • Substance P in heart failure: the good and the bad. (Dehlin HM, Levick SP) Int J Cardiol 2014 Jan 1;170(3):270-7 PMID: 24286592 PMCID: PMC4450674 11/30/2013
  • Estrogen modulates the influence of cardiac inflammatory cells on function of cardiac fibroblasts. (McLarty JL, Li J, Levick SP, Janicki JS) J Inflamm Res 2013;6:99-108 PMID: 24062614 PMCID: PMC3780290 09/26/2013
  • Substance P acting via the neurokinin-1 receptor regulates adverse myocardial remodeling in a rat model of hypertension. (Dehlin HM, Manteufel EJ, Monroe AL, Reimer MH Jr, Levick SP) Int J Cardiol 2013 Oct 12;168(5):4643-51 PMID: 23962787 PMCID: PMC4043399 08/22/2013
  • Alpha-calcitonin gene-related peptide is protective against pressure overload-induced heart failure. (Li J, Levick SP, DiPette DJ, Janicki JS, Supowit SC) Regul Pept 2013 Aug 10;185:20-8 PMID: 23816470 07/03/2013
  • Could interferon-gamma be a therapeutic target for treating heart failure? (Levick SP, Goldspink PH) Heart Fail Rev 2014 Mar;19(2):227-36 PMID: 23589353 PMCID: PMC3844057 04/17/2013
  • Gender differences in non-ischemic myocardial remodeling: are they due to estrogen modulation of cardiac mast cells and/or membrane type 1 matrix metalloproteinase. (Janicki JS, Spinale FG, Levick SP) Pflugers Arch 2013 May;465(5):687-97 PMID: 23417570 PMCID: PMC3654075 02/19/2013
  • Stem cell factor is responsible for the rapid response in mature mast cell density in the acutely stressed heart. (Li J, Lu H, Plante E, Meléndez GC, Levick SP, Janicki JS) J Mol Cell Cardiol 2012 Oct;53(4):469-74 PMID: 22850284 PMCID: PMC3438908 08/02/2012
  • Alterations in cardiac structure and function in a murine model of chronic alcohol consumption. (Law BA, Levick SP, Carver WE) Microsc Microanal 2012 Jun;18(3):453-61 PMID: 22571914 05/11/2012
  • Estrogenic modulation of inflammation-related genes in male rats following volume overload. (McLarty JL, Meléndez GC, Levick SP, Bennett S, Sabo-Attwood T, Brower GL, Janicki JS) Physiol Genomics 2012 Mar 19;44(6):362-73 PMID: 22274565 PMCID: PMC3327141 01/26/2012
  • The convergence of ancient chinese medicine with modern therapeutics to prevent cardiac fibrosis. (Janicki JS, Levick SP) Am J Hypertens 2012 Feb;25(2):139 PMID: 22262254 01/21/2012
  • Isolation of functional cardiac immune cells. (McLarty JL, Meléndez GC, Spencer WJ, Levick SP, Brower GL, Janicki JS) J Vis Exp 2011 Dec 05(58) PMID: 22158428 PMCID: PMC3346052 12/14/2011
  • Prevention of adverse cardiac remodeling to volume overload in female rats is the result of an estrogen-altered mast cell phenotype. (Lu H, Meléndez GC, Levick SP, Janicki JS) Am J Physiol Heart Circ Physiol 2012 Feb 1;302(3):H811-7 PMID: 22160000 PMCID: PMC3353795 12/14/2011
  • Substance P induces adverse myocardial remodelling via a mechanism involving cardiac mast cells. (Meléndez GC, Li J, Law BA, Janicki JS, Supowit SC, Levick SP) Cardiovasc Res 2011 Dec 1;92(3):420-9 PMID: 21908647 PMCID: PMC3211974 09/13/2011
  • Tryptase/Protease-activated receptor 2 interactions induce selective mitogen-activated protein kinase signaling and collagen synthesis by cardiac fibroblasts. (McLarty JL, Meléndez GC, Brower GL, Janicki JS, Levick SP) Hypertension 2011 Aug;58(2):264-70 PMID: 21730297 PMCID: PMC3437478 07/07/2011
  • Cardiovascular changes during maturation and ageing in male and female spontaneously hypertensive rats. (Chan V, Fenning A, Levick SP, Loch D, Chunduri P, Iyer A, Teo YL, Hoey A, Wilson K, Burstow D, Brown L) J Cardiovasc Pharmacol 2011 Apr;57(4):469-78 PMID: 21283019 02/02/2011
  • Cardiac mast cells: the centrepiece in adverse myocardial remodelling. (Levick SP, Meléndez GC, Plante E, McLarty JL, Brower GL, Janicki JS) Cardiovasc Res 2011 Jan 1;89(1):12-9 PMID: 20736239 PMCID: PMC3002871 08/26/2010
  • Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. (Meléndez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL) Hypertension 2010 Aug;56(2):225-31 PMID: 20606113 PMCID: PMC2921860 07/08/2010
  • Inhibition of matrix metalloproteinase activity prevents increases in myocardial tumor necrosis factor-alpha. (Murray DB, Levick SP, Brower GL, Janicki JS) J Mol Cell Cardiol 2010 Aug;49(2):245-50 PMID: 20403361 PMCID: PMC2885505 04/21/2010
  • Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart. (Levick SP, Murray DB, Janicki JS, Brower GL) Hypertension 2010 Feb;55(2):270-6 PMID: 20048196 PMCID: PMC2823485 01/06/2010
  • TNF-alpha inhibition attenuates adverse myocardial remodeling in a rat model of volume overload. (Jobe LJ, Meléndez GC, Levick SP, Du Y, Brower GL, Janicki JS) Am J Physiol Heart Circ Physiol 2009 Oct;297(4):H1462-8 PMID: 19666842 PMCID: PMC2770768 08/12/2009
  • Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart. (Levick SP, McLarty JL, Murray DB, Freeman RM, Carver WE, Brower GL) Hypertension 2009 Jun;53(6):1041-7 PMID: 19398662 04/29/2009
  • Regulation of matrix metalloproteinases is at the heart of myocardial remodeling. (Levick SP, Brower GL) Am J Physiol Heart Circ Physiol 2008 Oct;295(4):H1375-6 PMID: 18757475 PMCID: PMC2593525 09/02/2008
  • Protection from adverse myocardial remodeling secondary to chronic volume overload in mast cell deficient rats. (Levick SP, Gardner JD, Holland M, Hauer-Jensen M, Janicki JS, Brower GL) J Mol Cell Cardiol 2008 Jul;45(1):56-61 PMID: 18538342 PMCID: PMC3272272 06/10/2008
  • A novel technique for isolating functional mast cells from the heart. (Morgan LG, Levick SP, Voloshenyuk TG, Murray DB, Forman MF, Brower GL, Janicki JS) Inflamm Res 2008 May;57(5):241-6 PMID: 18465084 05/10/2008
  • Response of cardiac mast cells to atrial natriuretic peptide. (Murray DB, Gardner JD, Levick SP, Brower GL, Morgan LG, Janicki JS) Am J Physiol Heart Circ Physiol 2007 Aug;293(2):H1216-22 PMID: 17434981 04/17/2007
  • Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. (Brower GL, Levick SP, Janicki JS) Am J Physiol Heart Circ Physiol 2007 Jun;292(6):H3057-64 PMID: 17308006 02/20/2007
  • Arachidonic acid metabolism as a potential mediator of cardiac fibrosis associated with inflammation. (Levick SP, Loch DC, Taylor SM, Janicki JS) J Immunol 2007 Jan 15;178(2):641-6 PMID: 17202322 01/05/2007
  • The relationship between myocardial extracellular matrix remodeling and ventricular function. (Brower GL, Gardner JD, Forman MF, Murray DB, Voloshenyuk T, Levick SP, Janicki JS) Eur J Cardiothorac Surg 2006 Oct;30(4):604-10 PMID: 16935520 08/29/2006
  • Antifibrotic activity of an inhibitor of group IIA secretory phospholipase A2 in young spontaneously hypertensive rats. (Levick S, Loch D, Rolfe B, Reid RC, Fairlie DP, Taylor SM, Brown L) J Immunol 2006 Jun 1;176(11):7000-7 PMID: 16709861 05/20/2006
  • Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affecting blood pressure in DOCA-salt hypertensive rats. (Loch D, Levick S, Hoey A, Brown L) J Cardiovasc Pharmacol 2006 Mar;47(3):396-404 PMID: 16633082 04/25/2006
  • Reversal of cardiac dysfunction by selective ET-A receptor antagonism. (Allan A, Fenning A, Levick S, Hoey A, Brown L) Br J Pharmacol 2005 Nov;146(6):846-53 PMID: 16151437 PMCID: PMC1751222 09/10/2005
  • Increased calcium influx mediates increased cardiac stiffness in hyperthyroid rats. (Levick S, Fenning A, Brown L) Cell Biochem Biophys 2005;43(1):53-60 PMID: 16043883 07/27/2005
  • Last update: 09/16/2016